ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference

Rhea-AI Summary

ChromaDex Corp. (NASDAQ:CDXC) has announced that CEO Rob Fried and CFO Kevin Farr will present at Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference on June 15 at 3:45 p.m. Eastern Time. The presentation will be virtual, and the management team will also engage in one-on-one meetings with institutional investors throughout the day. ChromaDex is committed to healthy aging, focusing on research related to nicotinamide adenine dinucleotide (NAD+) and its precursor, nicotinamide riboside (NR), marketed as Niagen®.

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer’s 22^nd Annual Consumer Growth and E-Commerce Conference.

The ChromaDex management team is scheduled to present virtually on Wednesday, June 15^th at 3:45 p.m. Eastern Time (12:45 p.m. Pacific Time).

ChromaDex management will also attend virtual one-on-one meetings with institutional investors throughout the day.

Webcast link: ChromaDex Investor Presentation – Oppenheimer Consumer Conference

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.truniagen.com and through partnerships with global retailers and distributors. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006148/en/

ChromaDex Investor Relations Contact:

Brianna Gerber, Vice President of Finance and Investor Relations

949-419-0288 ext. 127

briannag@chromadex.com



ChromaDex Media Contact:

Kendall Knysch, Director of Media Relations

310-388-6706 ext. 689

kendall.knysch@chromadex.com

Source: ChromaDex Corporation

FAQ

What date is ChromaDex presenting at Oppenheimer’s conference?

ChromaDex will present on June 15 at 3:45 p.m. Eastern Time.

Who from ChromaDex will present at the conference?

CEO Rob Fried and CFO Kevin Farr will present.

What is the focus of ChromaDex's research?

ChromaDex focuses on nicotinamide adenine dinucleotide (NAD+) and its precursor nicotinamide riboside (NR).

Where can I find the webcast link for ChromaDex’s presentation?

The webcast link can be found in their press release or on their investor relations page.

What is ChromaDex's primary product?

ChromaDex's primary product is Tru Niagen®, which features the NAD+ precursor nicotinamide riboside.